ABSTRACT
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) designates a heterogenous set of diseases histologically mimicking alcoholic liver disease though observed in insulin-resistant nonalcoholic individuals, in the absence of competing etiologies of liver disease [1, 2] . The NAFLD spectrum and its natural history span simple steatosis through nonalcoholic steatohepatitis (NASH), fibrosis-cirrhosis, and, in a subset of cases, hepatocellular carcinoma (HCC), with or without cirrhosis [3, 4] . On the basis of the epidemic prevalence of disease and its inherent hepatic, metabolic, oncologic, and cardiovascular disease burden, NAFLD is a major public health issue posing heavy costs on health systems [1, [5] [6] [7] . From a pathophysiological point of view, intrahepatic storage of triglycerides (TGs) is an example of an adaptive process becoming maladaptive, given that ectopic fat gives rise to lipotoxicity [8, 9] . Fatty changes will primarily result from excess de novo intrahepatic lipogenesis associated with the liver being overwhelmed by an excess of steatogenic substrates in the setting of insulin resistance (IR), impaired glucose disposal/type 2 diabetes (T2D), hyperlipidemia, visceral obesity, and other features of the metabolic syndrome (MetS) [10] . Steatosis will also derive from the failure of the liver to oxidize and export excess lipids [3, [11] [12] [13] . Therefore, NAFLD can best be conceptualized as an abnormal storage of TGs resulting from an imbalance between intrahepatic synthesis and catabolism/disposal of fatty substrates [14] , which is inextricably linked to IR/T2D and atherogenic dyslipidemia [13, 15] .
Nuclear receptors (NRs) are transcriptional factors which, activated by ligands, are master regulators of metabolism and also have intricate connections with circadian control accounting for cyclical patterns in the metabolic fate of nutrients [16] . Several transcription factors, such as peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), and farnesoid X receptors (FXRs), finely regulate energetic fluxes and metabolic pathways via the molecular cascades they trigger [17] . Dysregulation of such pathways is heavily implicated in those metabolic derangements typically belonging to the domain of IR and MetS and in the histogenesis of progressive NAFLD forms and their clinical complications in both adults and children [3, 16, 18, 19] .
On these grounds, dietary and pharmacological manipulation of NRs has become a major aim in the research concerning NAFLD treatment. The present article critically reviews the role of NRs in the pathogenesis of NAFLD and explores how this information may potentially be exploited in the drug treatment of this condition. All of these pieces of information may be put into perspective on the basis of the analysis of the natural history of NAFLD ( Fig. 1 ).
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
PATHOPHYSIOLOGY OF PPARs
The PPARs are members of the NR superfamily including PPAR-a, PPAR-b/d, and PPAR-c, which play a key role in regulating cellular growth and differentiation, metabolism, and inflammation [20] [21] [22] . PPAR-a (NR1C1) is highly expressed in liver, kidney, and muscle, while PPAR-c Fig. 1 Overview of the role of nuclear receptors in the pathophysiology, natural course, and treatment of NAFLD based on data discussed in the present review article. This cartoon aims to summarize the specific roles played by PPARs, FXR, and LXR in the development and progression of NAFLD. Pathophysiology PPAR-a promotes b-oxidation of FA in the hepatocytes and exerts lipid-lowering activity; PPAR-c, abundantly expressed in the adipose tissue, promotes adipocyte differentiation and storage of triglycerides and has an insulin-sensitizing activity by protecting non-adipose tissues against excessive fat deposition and by increasing adiponectin secretion; PPAR-b/ d stimulates glycolysis and inhibits gluconeogenesis in the liver, promotes b-oxidation of FA in the muscle, and exerts an anti-inflammatory role; LXR controls cholesterol lipoprotein metabolism and modulates immune, inflammatory, and fibrogenic responses; FXR regulates bile acid homeostasis and also lipoprotein-glucose metabolism. Natural course The schematic figure recapitulates the chief role of nuclear receptors in the natural history of NAFLD. Drug treatment The potential role of drugs interacting with each of the individual classes of nuclear receptors is also illustrated. FA fatty acids, FXR farnesoid X receptor, HDL high-density lipoprotein, LDL low-density lipoprotein, LXR liver X receptor, NAFLD nonalcoholic fatty liver disease, PPAR peroxisome proliferator-activated receptor, PUFA polyunsaturated fatty acids, TG triglycerides, VLDL very-low-density lipoprotein
Role of PPAR-a in Metabolism
In hepatocytes, PPAR-a acts as a nutritional sensor, modulating the rates of FA catabolism, lipogenesis, and ketone body synthesis in response to feeding and starvation [22] . PPAR-a controls the expression of genes regulating peroxisomal/mitochondrial 
Role of PPAR-a in NAFLD
The effect of PPAR-a system activation in improving the NAFLD spectrum has been studied in several animal models, which recapitulate human disease to a partial extent 
Role of PPAR-c in Metabolism
PPAR-c is abundantly expressed in the adipose tissue where it enhances the activation of genes promoting adipocyte differentiation and storage of TG [14, 16, 20, 21] . Moreover, PPAR-c is a key regulator of glucose homeostasis through its insulin-sensitizing activity by protecting non-adipose tissues against excessive fat deposition and by balancing the secretion of adipocytokines [47] .
Role of PPAR-c in NAFLD
PPAR-c is generally increased in fatty liver associated with obesity both in mouse models, 
NATURAL HISTORY OF NAFLD AT A GLANCE AND ROLE OF NRS
Although the basic pathological steps of NAFLD for NASH to progress from early, non-fibrosis disease to cirrhosis, which confirms that, although they form a disease spectrum, these two conditions follow a fairly distinct course.
Although, sometimes, simple steatosis is alluded to as 'nonalcoholic fatty liver' it is, nevertheless, a disease which is worth treating not only to untrigger its potential progression to NASH but also to reduce the risk of [128] . Consistently, PPAR-a activation improves hepatic IR and steatosis in high-fructose-diet-fed mice [129] .
PPAR-c is upregulated in the liver of obese patients [130, 131] . Conversely, dietary short-chain FA supplementation prevented and reversed HFD-induced metabolic abnormalities in mice by decreasing PPAR-c expression and activity therefore switching metabolic pathways from the synthesis of lipids to their utilization [132] . Interestingly, genetic PPAR-c variants are associated with the development and histological progression of human NAFLD [133] . Age, gender, and genetic and metabolic factors are independently associated with NASH [135] [136] [137] [138] [139] [140] [141] . At variance with vitamin E and OCA, thiazolidinediones do not reverse hepatocyte balloning suggesting that IR plays a key role in the early phases of disease only [142] .
Role of LXR in Hepatic Inflammation
Once activated by elevated intracellular cholesterol levels, LXRs induce the expression of genes controlling the absorption, efflux, transport, and excretion of cholesterol. [160] [161] [162] . In particular, the Rotterdam study conducted with transient elastography in 3041 participants found that the combined presence of T2D and steatosis was strongly associated with liver stiffness (8.0 kPa), suggestive of clinically relevant fibrosis [161] .
Role of FXR in Hepatic Fibrogenesis
CDC is the natural agonist of FXR, the nuclear hormone receptor which regulates gluco-lipidic metabolism, senses BA, and inhibits BA synthesis by inducing SHP gene expression [163] .
Moreover, FXR plays a major role in experimental hepatic fibrosis and in fibrosing kidney disorders observed in diabetic humans [164, 165] . Interestingly, the expression of FXR is reduced in human and mice fibrotic livers [166] .
Experimental evidence supports that an FXR-SHP regulatory cascade promotes the reversal of hepatic fibrosis, suggesting that FXR ligands might be effective antifibrotic agents [163] . Consistently, a phase 2 trial has shown that the administration of OCA, a semisynthetic derivative of CDC, reduced surrogate markers of liver inflammation and fibrosis in patients with NAFLD and T2D [167] . The role of OCA is further discussed in ''Drugs Interacting with FXR'' below.
Hepatocellular Carcinoma
HCC is the end stage of NAFLD as well as of other chronic liver disorders due to varying etiology. At variance with other etiologies, however, NAFLD-HCC is associated with a less striking prevalence in the male gender and may occur in the absence of cirrhosis [168] [169] [170] . Given that these NAFLD individuals escape surveillance programs, NAFLD-HCC often undergoes a diagnostic delay which curtails the chances for radical treatment and accounts for a worse prognosis compared to other etiologies of disease, such as hepatitis B virus (HBV)-HCC and HCV-HCC [171, 172] .
Several Table S1 in the supplementary material).
Fibrates and Polyunstaurated FA
Treatment with drugs interacting with PPAR-a, such as fibrates and PUFA, has failed to improve NAFLD histology in humans. In particular, despite certain favorable metabolic effects, fibrate monotherapy improves liver histology only to a minimal extent [186] [187] [188] [189] [190] . Similarly, PUFA supplementation may ameliorate some metabolic parameters and probably reduces liver fat content, but has no effect on liver inflammation and fibrosis [191] [192] [193] [194] [195] [196] .
Paradoxically, a recent study suggested that PUFA treatment may even worsen IR and liver histology in diabetic patients with NASH [197] . Accordingly, despite improving dyslipidemia [198, 199] [211] , and, on the other hand, treatment extension over time has not been associated with additional improvement of NASH histological features [206] .
Thiazolidinediones promote pre-adipocyte differentiation into small, insulin-sensitive adipocytes and induce weight gain attributable to an increase in adipose tissue mass through a redistribution of fat from ectopic sites, such as the liver and muscle, to the more physiological reservoir, the peripheral subcutaneous adipose tissue [206, 212] . Recent data suggest that a plateau phenomenon in the improvement in liver steatosis and inflammation probably occurs under PPAR-c agonists, once the individual subcutaneous adipose tissue expandability reaches its storage capacity [213, 214] . Moreover, thiazolidinediones are associated with long-term safety issues, such as an increased risk of congestive heart failure, bone fractures, and bladder cancer [215, 216] . For these reasons, the risk/benefit ratio of long-term treatment with PPAR-c agonists should be carefully assessed. Even though current guidelines suggest that pioglitazone can be used to treat biopsy-proven NASH in non-diabetic patients, thiazolidinediones are not specifically licensed for the treatment of NASH implying that off-label administration poses an additional burden of responsibilities on the individual prescribing physician [2, 217] . The available weaponry spans from simple lifestyle changes to drugs (licensed for conditions other than NAFLD) to endoscopic and surgical procedures (aimed to treat obesity and indirectly improving NAFLD). However no 'ideal', 'one-fits-all' approach is available to target all the aims listed above. Rather, a highly tailored management approach should best be implemented on the basis of age, stage of liver disease, and systemic co-morbidity [231] .
Lifestyle Changes
Diet A 7-10% weight loss is associated with histologically significant rewards such as reduced liver fat content, remission of NASH, and fibrosis reduction [232] . Moreover, quality of life is also improved in these patients as a result of weight loss [233] . Further to total ingested calories, saturated fats, carbohydrates, and fructose-rich beverages all need to be restricted and, conversely, increases in MUFA, long-chain PUFA, and caffeine should be promoted [234] .
Physical Exercise
There is clear meta-analytic evidence that exercising reduces liver fat content irrespective of weight loss [235] . This is of interest given the low cost and widespread availability of this option and that most patients fail to maintain weight loss over time. Aerobic training is superior to progressive resistance training [236] .
On the basis of guidelines, cardiorespiratory exercise training should be regularly performed [237] .
Drug Treatment

Lipid-Lowering Agents
Cardiovascular disease is the leading cause of mortality in NAFLD patients and guidelines recommend the use of statins in these individuals. However, statins are underutilized in patients with NAFLD owing to implicit concerns of hepatotoxicity [238, 239] .
There is no relationship linking reduction in LDL cholesterol values and raised transaminases, and hypertransaminasemia is linked to statin dosage and physicochemical properties [240, 241] . Moreover, statins improve symptom-free survival from cardiovascular disease selectively in those patients in whom coronary artery disease coexists with NAFLD [242] . Recent evidence also suggests that statin use improves liver histology and protects from NASH, in a dose-dependent manner, both in diabetic and non-diabetic individuals [124, 243] .
Although fibrates do not improve NAFLD histology, they do offer a safe and effective treatment for dyslipidemic patients with NAFLD [226] .
Antidiabetics
NAFLD is exceedingly common among those with T2D [244] ; conversely, a subset of NAFLD individuals have T2D at baseline and a large proportion of them will develop T2D over a 5-year follow-up [227, 244, 245] . Principles of treatment of T2D in NAFLD have recently been discussed elsewhere [226] . Probably, the most exciting novel finding in this arena is the possibility to implement a chemopreventive strategy of HCC with antidiabetic medications such as discussed below.
Antihypertensives
In NAFLD patients, arterial hypertension is the least prevalent among the individual features of the MetS [244] and, nevertheless, it is a major risk factor for the progression of hepatic fibrosis in these patients [120] , which raises the possibility that, by treating high blood pressure with sartans, hepatic fibrosis progression may be halted. Proof-of-concept experimental studies consistently support this notion [246] [247] [248] [249] [250] [251] [252] [253] .
Obesity
Endoscopic Procedures
BioEnterics intragastric balloon safely induces a sustained weight loss with diet support or for preparing patients for bariatric surgery. Those individuals attaining a BMI reduction greater than 10% experience improvement in biochemical surrogate indices of NAFLD, IR, and NAS [254, 255] .
Surgery
Bariatric surgery in NAFLD improves transaminases, cardiometabolic risk factors (IR, glucose and lipid metabolism, hypertension), and histological endpoints (hepatic steatosis, steatohepatitis, and fibrosis); however, it is not qualified as a treatment option for NAFLD per se, but only for the accompanying morbid obesity [256] . Roux-en-Y gastric bypass (RYGB) is more effective than other types of surgery in inducing both weight loss and NAFLD improvement. However, additional studies designed to evaluate liver-specific mortality, liver transplantation, or quality of life are eagerly awaited [256] .
NASH-Cirrhosis
General principles of management of cirrhosis are fully covered elsewhere [159, [257] [258] [259] .
Here we discuss some selected topics of specific relevance to NASH-cirrhosis.
Prevention of Cirrhosis via Antifibrotic Agents
This aim remains largely unaddressed in clinical practice. A recent survey reporting that aspirin use seems to exert a protection from fibrosis in the general population paves the way for randomized clinical trials (RCTs) in individuals with NASH [260] . Moderate-quality network meta-analytic evidence supports the superiority of pentoxifylline and OCA over placebo in improving fibrosis [125] .
Prevention of Portal Vein Thrombosis
Portal vein thrombosis (PVT) is a major event dictating the natural history of cirrhosis irrespective of etiology and the prevention of PVT with enoxaparin is associated with decreased hepatic decompensation and improved survival [261] . As regards the relationship of the etiology of cirrhosis with the risk of PVT, a nationwide US survey enrolling, overall, 33,368 patients who underwent liver transplantation reported that NASH cirrhosis was the strongest risk factor independently associated with PVT [229] . These data attest that NASH is a prothrombotic state and suggest that PVT prevention may be particularly indicated in this population. RCTs should assess which anticoagulants should be used in preventing PVT effectively and safely in this specific patient population.
Chemoprevention of HCC
The molecular bases of this topic have extensively been examined [176, 230] . In short, on the basis of current evidence metformin [262, 263] , statins [264, 265] , or their combination [266] may potentially be useful in this setting. However, most data derive from observational studies and RCTs are warranted before chemoprevention of HCC can be licensed for clinical practice.
CONCLUSIONS
Our understanding of the role of NRs in NAFLD pathophysiology, natural history, and treatment is preliminary (Fig. 1) 
